Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

About Pacira Pharmaceuticals

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PCRX
  • CUSIP: 69512710
Key Metrics:
  • Previous Close: $33.15
  • 50 Day Moving Average: $36.34
  • 200 Day Moving Average: $42.31
  • 52-Week Range: $31.08 - $80.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 26.95
  • P/E Growth: 1.38
  • Market Cap: $1.24B
  • Outstanding Shares: 37,278,000
  • Beta: 1.96
  • Net Margins: -4.21%
  • Return on Equity: 0.02%
  • Return on Assets: 0.01%
  • Current Ratio: 1.72%
  • Quick Ratio: 1.31%
Additional Links:
Companies Related to Pacira Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (?)
Ratings Breakdown: 4 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $73.18 (120.76% upside)

Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateFirmActionRatingPrice TargetDetails
10/27/2016BMO Capital MarketsUpgradeUnderperform -> Market Perform$36.00 -> $35.00View Rating Details
10/19/2016WedbushLower Price TargetOutperform$109.00 -> $93.00View Rating Details
10/14/2016Cowen and CompanyReiterated RatingHoldView Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldView Rating Details
9/26/2016Jefferies GroupReiterated RatingBuy$74.00 -> $60.00View Rating Details
8/3/2016Piper Jaffray Cos.Reiterated RatingOverweight$81.00View Rating Details
8/2/2016MizuhoReiterated RatingBuy$64.00View Rating Details
4/20/2016Canaccord GenuityReiterated RatingBuyView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00View Rating Details
1/29/2016Bank of America Corp.UpgradeNeutral -> Buy$75.00View Rating Details
1/9/2016Leerink SwannReiterated RatingHoldView Rating Details
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00View Rating Details
9/24/2015Barclays PLCReiterated RatingBuyView Rating Details
1/30/2015Goldman Sachs Group Inc.Boost Price Target$126.00View Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016Q316$0.03$69.50 millionListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
Current Year EPS Consensus Estimate: $0.35 EPS
Next Year EPS Consensus Estimate: $1.23 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.20)($0.20)($0.20)
Q3 20161$0.03$0.03$0.03
Q4 20161$0.00$0.00$0.00
(Data provided by Zacks Investment Research)


Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Ownership Percentage: 6.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateHeadline logoWhat Falling Estimates & Price Mean for Pacira Pharmaceuticals (PCRX) - Nasdaq (NASDAQ:PCRX) - October 26 at 6:47 PM
News IconNoteworthy Analyst Ratings of Two Stocks: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), Clovis Oncology, Inc ... - The Voice Registrar (NASDAQ:PCRX) - October 26 at 6:47 PM
News IconTechnical Analysis Don't Lie: Pacira Pharmaceuticals Inc on Focus After Forming Bearish Double Bottom Chart Pattern - Chester News (NASDAQ:PCRX) - October 26 at 6:46 PM
News IconIs Momentum Mounting for Pacira Pharmaceuticals Inc. (PCRX) - Wall Street Confidential (NASDAQ:PCRX) - October 23 at 6:29 PM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Is Expected To Post EPS Of $0 - (NASDAQ:PCRX) - October 23 at 6:29 PM
News IconPacira Pharmaceuticals Inc. (PCRX) stock slides, "Hold" rating reaffirmed by Cowen and Company Analysts - BNB Daily (blog) (NASDAQ:PCRX) - October 17 at 11:51 AM
News IconToday's Ownership Action: Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Institutional Investor Sentiment Is 1.34 - Post News (NASDAQ:PCRX) - October 12 at 6:38 PM
News IconStock Forging Ahead with Pace: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - CSZ News (NASDAQ:PCRX) - October 11 at 7:00 PM
News IconStock Perspective: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Earnings in View - CSZ News (NASDAQ:PCRX) - October 8 at 6:11 PM
News IconThe Statistics Don't Lie: Pacira Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:PCRX) - October 6 at 12:11 PM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Sell Recommendations At 0 - Investor Newswire (NASDAQ:PCRX) - October 5 at 6:33 PM logoPacira Pharmaceuticals Becomes Oversold (PCRX) - Nasdaq (NASDAQ:PCRX) - October 1 at 11:58 AM
News IconShares Slipping Lower Over the Past Month: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Post News (NASDAQ:PCRX) - September 29 at 6:38 PM
News Icon2 Stocks Analyst-Opinion Need Close Attention Palatin Technologies, Inc. (NYSEMKT:PTN), Pacira Pharmaceuticals ... - The Voice Registrar (NASDAQ:PCRX) - September 27 at 11:19 AM logoAnalyst Update: Himax Technologies, Inc., Pacira Pharmaceuticals Inc, and RetailMeNot Inc (NASDAQ:PCRX) - September 26 at 6:48 PM logoPACIRA PHARMACEUTICALS : Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures (NASDAQ:PCRX) - September 22 at 6:22 PM logoCompany Update (NASDAQ:PCRX): Pacira Pharmaceuticals Inc Announces Official Launch of EXPAREL (NASDAQ:PCRX) - September 22 at 11:33 AM logoPacira Pharmaceuticals Inc (NASDAQ:PCRX) Launches Exparel As Opioid Alternative In Pain Management (NASDAQ:PCRX) - September 22 at 11:33 AM logoCompany Update (NASDAQ:PCRX): Pacira Pharmaceuticals Inc Announces Official Launch of EXPAREL - Smarter Analyst (NASDAQ:PCRX) - September 21 at 6:20 PM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) EPS Projection At $0.15 - Investor Newswire (NASDAQ:PCRX) - September 12 at 6:23 PM
News IconShares Lower Over the Past Quarter: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Post News (NASDAQ:PCRX) - September 10 at 5:58 PM
News IconDrw Securities adds Pacira Pharmaceuticals Inc (PCRX) to its portfolio - National Daily Press (NASDAQ:PCRX) - September 10 at 10:55 AM
News IconPlacing Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Shares Under the Microscope - Post News (NASDAQ:PCRX) - September 9 at 11:28 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) From The Analysts Point of View - National Daily Press (NASDAQ:PCRX) - September 9 at 11:28 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX): What is the Sell-side Making of this Stock? - National Daily Press (NASDAQ:PCRX) - September 9 at 11:28 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) From The Analysts Point of View (NASDAQ:PCRX) - September 8 at 6:28 PM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Is Expected To Post EPS Of $0.15 (NASDAQ:PCRX) - September 4 at 10:46 AM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Is Expected To Post EPS Of $0.15 - (NASDAQ:PCRX) - September 3 at 5:55 PM logoArray (ARRY) Oncology Drug Accepted for Review in the U.S. (NASDAQ:PCRX) - September 2 at 11:35 AM logoAmarin (AMRN) Ends Patient Randomization in Vascepa Study (NASDAQ:PCRX) - September 1 at 9:51 AM logoPacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:PCRX) - September 1 at 9:51 AM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:PCRX) - August 24 at 6:30 PM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Reports Sales Of $69.64, Surprising Estimates By 3.074% - Investor Newswire (NASDAQ:PCRX) - August 23 at 11:11 AM logoWill Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Hit $109 Price Target? - Investor Newswire (NASDAQ:PCRX) - August 18 at 6:55 PM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX): Updated Analyst Ratings - Review Fortune (NASDAQ:PCRX) - August 8 at 11:27 AM
News IconPacira Pharmaceuticals Inc. (NASDAQ:PCRX) reported a second-quarter loss (NASDAQ:PCRX) - August 7 at 10:50 AM logoPacira Pharmaceuticals Inc. (PCRX) Jumps 19.05% on August 04 - (NASDAQ:PCRX) - August 5 at 6:59 PM
News IconTeekay Corporation (NYSE:TK) & Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Trend Analysis Report - Money News (press release) (NASDAQ:PCRX) - August 5 at 6:59 PM logoMajor Averages Close Thursday's Session Mostly Unchanged (NASDAQ:PCRX) - August 4 at 5:55 PM logoWhy Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today (NASDAQ:PCRX) - August 4 at 1:13 PM logoPacira Pharmaceuticals Inc. (PCRX) is Trading Higher on Unusual Volume for August 01 - (NASDAQ:PCRX) - August 3 at 10:00 AM logoCan Shares Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Hit $105? - Investor Newswire (NASDAQ:PCRX) - July 28 at 7:01 PM
News IconThe Statistics Don't Lie: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Earnings Preview - The Voice Registrar (NASDAQ:PCRX) - July 22 at 6:36 PM logoIs $105 Price Target Attainable For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)? - Investor Newswire (NASDAQ:PCRX) - July 21 at 7:05 PM logoAnalysts Reviewing Stocks: CVS Health Corporation (NYSE:CVS) , Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Street Updates (NASDAQ:PCRX) - July 21 at 7:05 PM logoPacira Pharmaceuticals Inc. (PCRX) Jumps 7.96% on July 20 - (NASDAQ:PCRX) - July 21 at 7:05 PM logoPacira Pharmaceuticals Inc (NASDAQ:PCRX) Realized Volatility Hits A Notable High - CML News (NASDAQ:PCRX) - July 21 at 7:05 PM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Expected To Post Sales Of $1127.9 - Investor Newswire (NASDAQ:PCRX) - July 19 at 7:09 AM
News IconShares Experiencing a Downtrend: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - TGP (NASDAQ:PCRX) - July 17 at 10:57 AM logoPacira Pharmaceuticals Inc. (PCRX) Drops 5.87% on July 13 - (NASDAQ:PCRX) - July 15 at 11:49 AM


Pacira Pharmaceuticals (NASDAQ:PCRX) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by Staff